Minister for Commercial Affairs, Head of Economic and Trade Mission Embassy Of Israel, Berlin
Doron Abrahami is the Minister for Commercial Affairs and Head of the Economic and Trade Mission in the Israeli Embassy in Berlin. He is an industrial engineer by profession and holds a Master in Public Policy.
Being a career diplomat, Mr. Abrahami had formerly served as the Commercial Attaché of Israel in Athens, Greece, as the Consul for Economic Affairs in Los Angeles, California and as the Consul for Economic Affairs of Israel in Istanbul, Turkey.
Before leaving to Berlin, Mr. Abrahami headed the administration for Environment and Sustainable Development at the Ministry of Economy in Jerusalem for the past five years. His main task was to promote economic development while protecting the environment and natural resources.
Mr. Abrahami specializes in energy, environment and sustainable development, and in finding marketing channels for the Israeli industry.
Patent Attorney & Partner, ULLRICH & NAUMANN, Heidelberg
Stefanie Beck is Patent Attorney, European Trademark and Design Attorney and partner at ULLRICH & NAUMANN PartG mbB in Heidelberg.
Stefanie is committed to ensure that innovations remain her clients’ property and to provide them with her comprehensive and, importantly, tailored advice, highlighting all possibilities of protecting their IP. In her law firm she covers Patent, utility, design and trademark law, infringement proceedings, licensing and employee invention law. One of her main technical areas is medical engineering.
Her clients include large corporate companies with in-house patent departments, small and medium-sized enterprises, start-ups and individual inventors. In addition, she represents national as well as international research institutions.
Before working in the field of IP and studying law for Patent Attorneys she studied Industrial Engineering at the Karlsruhe Institute of Technology (KIT) and Technology Management and Entrepreneurship at the École polytechnique fédérale de Lausanne (EPFL).
VR Consultant, Berlin
Thomas Bedenk is Freelance Virtual Reality Consultant. From 2009 until 2015 he was Creative Director, Managing Director and Co-Founder of Brightside Games. He studied Media Design in Nuremberg and Human Factors in Berlin. He is teaching various game related subjects at game schools and universities. Before focusing on the games industry he was freelance interactive designer and developer for about 10 years and worked on special effects in the movie industry for a while. He started his love for games playing Pac-Man against his twin brother on the Atari 800XL and developed his first own games 1996.
Co-head, IOME, Riyadh, KSA
Ida Beerhalter heads IOME, a private investment partnership of women principals from the Gulf region with its head office in Riyadh, KSA.
Additionally, Mrs Beerhalter also serves as Member of the Board, Trustee, Advisor, and Expert to various for-profit and not-for-profit organizations around the globe (amongst others Astia USA, Omnia Strategy UK, WIP – Women in Parliaments Global Forum, Bellwald Partner GmbH Switzerland, Impact Investment Partners LLP UK, Sauti Kuu Foudation Kenya & Germany, Yunus Social Business GmbH Germany, Social Business Earth Switzerland, First Light Trust UK, TBLI Group The Netherlands, Charité Entrepreneurship Summit Germany) specialized in a wide range of issues, including social business, entrepreneurship, impact investment, gender inclusiveness, women empowerment, investment in emerging markets, and wealth management, family governance and succession planning.
Executive Director, Head Life Science Center, Ernst & Young, Mannheim
Head of EY Life Science Center in Mannheim, Germany
Close collaboration with EY Global Life Science Center in New York/ Boston
Sponsoring member of Bio Deutschland (German biotech industry association)
Role at EY:
Providing input to EY´s biotech and medtech thought leadership reports
Author of German biotech report
Assisting advisory client projects as an industry expert (transactions, performance improvement, risk management, assurance)
Prior to joining EY:
14 years in the pharmaceutical industry
BASF Pharma / Knoll AG, Abbott
In various functions: drug discovery research, drug screening, drug development (ADME), R&D management
Post-doc scientist at German Cancer Research Institute; Heidelberg
cell biology research
PhD from University of Heidelberg
molecular biology, human medicine (medical school)
Areas of expertise:
In depth life science industry experience (trends, strategies, processes)
Experience in business assessment (technology, IP, product portfolio, market, competitiveness, regulatory compliance)
Go-to-market and project execution support, primarily in M&A, due diligence, valuation as well as advisory projects
Broad relationship network in life sciences industry (companies, investors and industry associations)
Annual EY thought leadership Reports: German biotechnology report, global biotechnology report, global medical technology report
International benchmark studies: life science strategies for several European countries / regions
Business assessments of European Life Science companies (pharma, biotech, medtech): technologies, product portfolio, market, business plan, business risks, compliance
Transaction advisory support: M&A, due diligence, valuation, purchase price allocation
Business advisory support: R&D portfolio management / operational excellence
Chief Scientific Officer, Alkahest, San Carlos, CA
Alkahest Inc, San Carlos, CA (2015-Present)
Chief Scientific Officer
Rutgers University, New Brunswick, NJ (2017-Present)
Adjunct Associate Professor, Neurology
MentiNova Inc, New Brunswick, NJ (2013-Present)
Circuit Therapeutics Inc, Menlo Park, CA (2012-2015)
Senior Vice President of Research
Signum Biosciences Inc, Monmouth Junction, NJ (2010-2012)
Senior Vice President of Drug Discovery
Wyeth/Pfizer, Princeton, NJ (2006-2010)
Head, Cellular Neurodegeneration and Regeneration Group, Neuroscience Research Principal Research Scientist, Neurodegeneration Research
AGY Therapeutics Inc, South San Francisco, CA (2001-2006)
Program Leader/ Senior Scientist
Vice President, MacDougall Biomedical Communications, Munich
Mario Brkulj is a Vice President at MacDougall Biomedical Communications with 15 years of experience in life sciences communications, including investor and media relations, and journalism. Prior to joining MBI in 2015, Mario was Associate Director of Corporate Communications and Investor Relations at MorphoSys AG, a leading biopharmaceutical company in the monoclonal antibody space. During his time at MorphoSys, the Company evolved from a micro-cap fee-for-service oriented business predominantly owned by retail investors and institutions in Europe towards a fully-integrated drug development organization with a market cap of around €2 billion and a strong US healthcare investor base. As part of the Corp.Comm. & IR team, Mario was responsible for all aspects of corporate external communications and investor relations. Before MorphoSys, Mario was Company News Editor at Berlin-based BIOCOM AG, publisher of the leading German trade publication ”transkript”, and News Editor Central and Eastern Europe for the magazine “European Biotechnology News”. Mario graduated from Julius-Maximilians-Universität Würzburg with a Bachelor’s degree in biology.
Senior Regulatory Project Manager, Regulatory Services, ICON, Clayton, NC
JoAnne has over 20 years of healthcare software experience, including over 15 years of medical device experience in software development, product/project management, quality assurance, and regulatory affairs. Over the past 20 years, she has worked with medical software for advanced clinical decision support systems, infusion pumps, oxygen delivery systems, perinatal systems, clinical information systems, home health, practice management, billing, and durable medical equipment. JoAnne has experience with various Class II devices and has specific expertise in design controls, agile software development methods, human factors, risk management, cybersecurity, study data analysis, and quality systems. Prior to coming to ICON, she served as Director of Regulatory Affairs and Quality at a medical device start-up company in the personalized medicine space. JoAnne is a member of the Regulatory Affairs Professionals Society. She holds a B.S. in computer science from Louisiana Tech University and is Regulatory Affairs Certified.
Senior Vice President, Business Development, Cooley, Boston
Charlie Cameron has over 25 years of business development, investing and management consulting experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies, judges numerous business plan competitions and is a frequent speaker on innovation and entrepreneurship. He founded the Hub Angel Investment Group, which is on its fifth fund. He works with a plethora of entrepreneurs, innovators and investors in Europe, with special focus on DACH countries. Charlie is also Senior VP of Strategy at Cooley LLP, a global law firm with deep experience working with life science and tech companies and venture funds. He is on the board of the German American Business Council, Boston, the advisory board of the German Accelerator Life Science, and several other boards and advisory groups. During the past decade, Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Massachusetts.
Emmanuelle Marie Charpentier
Director, Max Planck Institute for Infection Biology, Berlin
Emmanuelle Marie Charpentier
Professor Emmanuelle Charpentier is a French microbiologist, geneticist and biochemist. She is Scientific Member of the Max Planck Society, Max Planck Director, Honorary Professor at Humboldt University, and recipient of an Alexander von Humboldt Professorship in Germany. She is also Visiting Professor at the Laboratory for Molecular Infection Medicine Sweden at Umeå University in Sweden. Emmanuelle has recently been recognized for her innovative research that laid the foundation for the ground-breaking CRISPR-Cas9 genome engineering technology. She has received numerous prestigious awards and distinctions, and is an elected member of national and European academies of sciences. She is co-founder of CRISPR Therapeutics and ERS Genomics.
Physician Advisor & Digital Health Strategist, New York
Fondly known as “drPhil”, the good doctor is a successful physician, healthcare executive, serial entrepreneur, and angel investor. Clinically trained in Emergency Medicine and Primary Care, Dr. Christian served as VP and Physician Executive for Bravo Health, the mid-1990’s, venture backed start-up that established the national model for risk-bearing provider groups, and was a progenitor of evidence-based medical practice and personalized healthcare. The company’s $540M acquisition was a testament to the validity and scalability of the clinical model designed, authored, implemented, and managed under “drPhil’s” guidance.
His additional professional activities have included medical directorships at some of country’s most prominent healthcare organizations, including: Blue Cross, UnitedHealthcare, Charter Health Plan, Bon Secours Health System, and HCR ManorCare.
As a Wharton Fellow, he became actively engaged in mentoring start-ups in digital health innovation, and served a tenure as Managing Director of Health at Dreamit Ventures, a Forbes Top 10 Venture Accelerator based in Philadelphia, PA.
Among his current professional activities, he serves as Chief Medical Officer of Florida-based American Health Associates, largest clinical diagnostic laboratory serving long-term care facilities in the United States. He holds Advisory, Board, and consulting positions with Fortune 100 healthcare companies and healthcare start-ups, and consults with some of the countries premier health corporations, accountable care organizations, digital health accelerators, insurers, and centers of health innovation, including: 500 Start-ups, StartUp Bootcamp, SXSW, Louisville Tech Summit, Merck Innovation, AARP, U.S. Dept. of Navy Innovation, Innova Health Systems, Baptist Health System, Johns Hopkins Medicine, Texas Children’s Medical Center, Catholic Health Initiative, Blue Cross/Blue Shield, Kaiser Permanente, and UnitedHealth/Optum. He holds a consulting portfolio of Silicone Valley Venture Capital and Private Equity Firms focused on digital health innovation, and maintains active clinical affiliations with healthcare institutions in Florida, Georgia, Maryland and Illinois.
drPhil has participated in medical missions in underserved countries across the globe; volunteers and fundraises for multiple charitable organizations; is a widely sought-after healthcare thought leader, and frequent speaker and panelist at international health innovation forums. An abbreviated list of certifications and memberships include: American College of Physician Executives, American College of Healthcare Executives, American College of Medical Practice Executives, American Society of Emergency Medicine, National Association of Managed Care Physicians, National Association of Health Services Executives, and The Society of Physician Entrepreneurs;
Federico Di Somma
Marketing & Communication Specialist, Sphingotec, Hennigsdorf
Federico Di Somma
2016 - Currently
Marketing & Communication Specialist
2015 - 2016
Basketball Virtus Roma
Press Officer and Marketing Assistant
2014 - 2015
Great - Global Research on Acute Conditions Team Italy
Communication and Event Manager
Worldwide Clinical Trials
King Of Prussia (PA), United States
2016 - 2017
LUISS Business School, Rome, Italy
Master of Science in Institutional Relations, Lobbying and Company Communication
Graduated with Honors
Thesis in: New opportunity and innovation for Acute Biomarkers in the Western Countries
2012 - 2014
Università Roma La Sapienza, Rome, Italy
Master of Science in International Relations
Graduated with Honors
Thesis: “The European Lobbying After the Treaty of Lisbon: A comparative Analysis“
2008 - 2012
Università Roma La Sapienza, Rome, Italy
Bachelor degree in Political Science and International Relations
Graduated with Honors
Thesis in "Strong and Weak interests in the European Lobbyng"
Director, Dept. of Experimental Neurology, Charité, Director, Center for Transforming Biomedical Research, BIH, Berlin
The research of Ulrich Dirnagl is focused on stroke, cerebral blood flow regulation, and brain imaging. In preclinical models as well as clinical trials he and his coworkers and collaborators explore mechanisms by which brain ischemia leads to cell death, and develops novel methods to intercept mechanisms of damage in acute brain damage, as well as to foster regeneration and repair of the lesions. He is particulary interested in how the brain protects itself (‘endogenous neuroprotection’), and how the brain interacts with other systems of the body after it has been injured. Closely linked to his interest in stroke pathophysiology is his interest in the coupling of regional blood flow to neuronal acitivity, the mechanism underlying functional brain imaging with MR and PET. Beyond imaging structure and function of the CNS he and his team are developing, validating and using techniques that allow the non-invasive imaging of brain biochemistry and molecular signaling. To this end they use optical, MR, and nuclear medicine approaches in mouse and man. To improve the predictiveness of preclinical translational research he is actively promoting the introduction of quality standards for experimental design and reporting, as well as international collaboration in large, phase III-type preclinical trials. Through meta-research he is trying to identify opportunities for improving research practice and to obtain evidence for the impact of targeted interventions. At the Charité Universitätsmedizin Berlin Ulrich Dirnagl serves as Director of the Department of Experimental Neurology. Since 2017 he is also the founding director of the Center for Transforming Biomedical Research (CTBR) at the Berlin Institute of Health. CTBR aims at overcoming the roadblocks in translational medicine by increasing the value and impact of biomedical research through maximizing the quality, reproducibility, generalizability, and validity of research.
Picture Credit: BIH - Thomas Rafalzyk
Head of Advisory Board, Professor & Managing Director, Department of Nephrology, Charité, Berlin
Duska Dragun has been a full professor at the Charité since 2008 and works as Managing Director at the Department of Nephrology and Intensive Care Medicine at Campus Virchow-Klinikum. She studied medicine in Zagreb, Croatia, until 1993 and received her doctoral degree from Humboldt University in Berlin. She has been awarded many national and international awards and fellowships. She is a member of the Editorial Board of “Transplantation” and has published over 100 peer-reviewed papers including publications in “Cell” and “The New England Journal of Medicine”.
President, SR One, Cambridge, MA
Jens Eckstein is president of SR One, the corporate venture capital arm of GlaxoSmithKline. He joined SR One from TVM Capital where he was last a venture partner, entrepreneur-in-residence and appointed CEO and president of SelectX Pharmaceuticals. Prior to that, he was a general partner in TVM’s Boston life sciences practice where he focused on earlier-stage investments. Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, he led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc.
Jens is currently chairman of the board of directors of Thrasos Therapeutics, and a director at Palleon Pharma, Decibel Therapeutics, ZappRx, Gladius Pharmaceuticals, and BioHealth Innovation (BHI). He was previously a member of the board of directors for Alios Biosciences, CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an advisor and board observer to Sirtris Pharmaceuticals.
He is the author of multiple scientific publications and holds several issued and pending patents. As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs.
Jens lives with his family in Cambridge, Massachusetts.
Vice President, Start-Up Division, Israel Innovation Authority, Tel Aviv
Anya Eldan is the VP, Start-Up Division at the Israel Innovation Authority (formerly the Office of Chief Scientist). Defining the policy and developing support programs to foster innovation in various industry segments, such as Early Stage Fund, Technological Incubators and Innovation Labs. Anya has over 30 years of Executive Experience in High Tech and Life Sciences companies, Venture Capital Investments and Technology Transfer ventures. Anya has a proven track record of private and public fundraising.
Jorge Juan Fernández
Head of Academics, Moebio, Biocat, Barcelona
Jorge Juan Fernández
Jorge has a dual affiliation. As Director of E-Health & Health 2.0 at Hospital Sant Joan de Déu (HSJD) in Barcelona, the largest children’s hospital in Spain and among the top 5 in Europe, he is responsible for “The Liquid Hospital”. This initiative encompasses more than 20 projects seeking to radically transform healthcare through an intensive use of technologies oriented towards the patient. HSJD aims to be a Liquid Hospital, providing services and content for the patients beyond the physical buildings of the hospital. HSJD is the most relevant example in Europe where a hospital is using online care, telemedicine, mobile apps and health 2.0 tools to put the patient in the center of care.
He is also the Head of Academics of Moebio, the disruptive talent development initiative by Biocat, aiming to accelerate healthcare entrepreneurship, which according to media is “probably the most impressive accelerator/ fellowship program we've seen emerge in Europe". The flagship program of Moebio is Design Health Barcelona, a 9-month postgraduate fellowship based on the successful Stanford Biodesign program, where interdisciplinary teams experience a full cycle of need identification, invention and early-stage implementation, performing a 2-month clinical immersion at top hospitals.
Jorge regularly acts as advisor and mentor to various healthcare start-ups and entrepreneurial acceleration programs across Europe: Healthbox (www.healthbox.com), BioEmprendedor XXI (http://www.bioemprendedorxxi.es/), Barcelona-MIT Mentoring Program. He is also a regular contributor to conferences such as Doctors 2.0 & You (Paris), Health 2.0 – Europe (London), Charité Entrepreneurship Summit (Berlin), etc.
He is also the author of “Las reglas de juego” (Leqtor Universal), a book on the principles and “laws” that govern Information and Technology. The book is an updated and expanded version of a free digital e-book that has been downloaded by more than 555.000 people, the most downloaded eBook in the history of Spanish Internet.
Jorge received his BSc degree on Economics from Universidad de Oviedo and a Masters degree in Economic and Political Theory from the London School of Economics and Political Science (LSE). He also holds a GMP from IESE Business School and a GSP from Singularity University. He has also followed executive education programs from leading institutions (Stanford University, Harvard Business School, Institute for Healthcare Improvement).
Jorge has been selected as 2014 European Young Leader “40 Under 40”.
Chair & W3 Professor, Department of Neurology, University of Greifswald, Greifswald
2017-now: Chair and W3 Professor, Department of Neurology at the University of Greifswald
2016: “Ruf”, W3-Professorship “Geriatrics” at the University of Göttingen, W3-Professorship “Translational Geriatrics” at the University of Jena
since 2013: Professor for Cognitive Neurology, NeuroCure Clinical Research Center, Charité
since 2010: Principal Investigator, NeuroCure Cluster of Excellence
since 2009: Principal investigator, Center for Stroke Research Berlin
since 2009: Professor for Cerebrovasc. Diseases, Senior Attending, Neurology, Charité
2008: Visiting scientist, Oxford Center for Functional MRI of the Brain, Oxford
2008: Postdoctoral thesis in Neurology, senior group leader, University of Münster
2007: Specialist exam (“Facharztprüfung”) in Neurology, junior attending
2005–2007: Training in Neurology, University of Münster
2005: Junior group leader, University of Münster
2002–2004: Postdoctoral fellowship (Supervisor: Dr. L. G. Cohen), National Institutes of Neurological Disorders and Stroke, US
1999–2002: Training in Neurology, University of Münster 1999 Dissertation, MD, University of Hannover 1992 – 1999 Studies in Medicine, University of Hannover
- Predictors of cognitive ability in aging: lifestyle, genetics, cardiovascular risk factors
- Modulation of learning by interventional strategies (pharmacology, non-invasive electrical brain stimulation, exercise, dietary) in older adults with and without cognitive impairment or after stroke
- Cognitive neurology and dementia (vascular and neurodegenerative type)
- Stroke and stroke sequelae: rehabilitation of cognitive and motor deficits after stroke
Founder & President, LabCentral, Cambridge, MA
Dr. Fruehauf is a physician-scientist and life science entrepreneur. He is the Founder, President and Executive Director of LabCentral, the largest co-working space for life-science companies in the Boston area. LabCentral is currently home to 29 high-potential startup companies and has graduated 20 companies. Companies at LabCentral have raised over $900MM since its opening in 2014. LabCentral was built around a concept of openness, transparency and shared resources that helps to accelerate the growth and increases the likelihood of success for science-based companies. ThermoFisher is a Platinum Sponsor at LabCentral.
Dr. Fruehauf is the Founder and CEO of Cambridge Biolabs, a service-provider to venture capital funds and startup companies in Kendall Square, which offers scientific due diligence pre-investment as well as pre-clinical CRO services to startups. Biolabs is expanding nationally and will or has opened similar co-working facilities in all of the major research hubs, starting with San Francisco, San Diego, New York City and Durham NC. Previously, he was a co-founder and Head of R&D at Cequent Pharmaceuticals, VP of R&D at Aura Biosciences, Co-founder at Vithera Pharmaceuticals and Deltix. He is General Partner at Bio-Innovation, a seed and early stage investment fund in the Boston area.
Dr. Fruehauf studied Medicine in Germany and France. He practiced medicine (internal medicine and OB/Gyn) for several years in Germany before coming to Boston for a post-doc at Beth Israel Deaconess Medical Center/Harvard Medical School. He is an author of 30 peer reviewed articles in the medical literature and inventor on a handful of issued and numerous pending patents, mostly on drug delivery and RNAi technologies.
Group Leader, German Center for Neurodegenerative Diseases, Berlin
Prof. Craig Garner received his doctoral degree in Biochemistry at Purdue University and did his postdoctoral studies at the Friedrich Miescher Institute in Basel, CH and was a junior group leader at the Center for Molecular Neurobiology in Hamburg. His most recent faculty appointment was at Stanford University as Professor in the Department of Psychiatry and Behavioral Science, where he co-directed the Stanford Down syndrome Center. In 2014, he became a Scientist/co-Speaker of the DZNE-Berlin: German Center for Neurodegenerative diseases and Professor at the Charité –Universitätsmedizin Berlin. In 2015, he co-founded SPARK-Berlin to help educate academic scholars about translation and entrepreneurship. He has also founded three biotech companies, “Balance Therapeutics”, “Stealth Biosciences” and Navan Technologies. He maintains an active basic research program focused on the molecular and physiological mechanisms of synapse assembly and function in health and neurodegenerative diseases.
Director Business Development, Trendlines Labs, Trendlines, Misgav
Nir Goldenberg brings extensive experience in business development, sales, and marketing in the medical device sector. At Trendlines Labs, Nir oversees the business development activities of the in-house innovation center, which evaluates critical unmet clinical needs, innovates technological solutions, and provides proof of concept and program risk mitigation at an early stage of development.
Prior to starting his work at Trendlines Labs, Nir served as Director of Commercial Development EU at INSIGHTEC Ltd, a global MR-guided focused ultrasound surgery company. Nir holds a B.Sc. in engineering from La Sapienza University of Rome.
Founder & CEO, Forever Healthy, Berlin
What started out more than 10 years ago as a personal quest of Michael to shed the numerous extra pounds and the extremely unhealthy lifestyle he acquired while building WEB.DE, turned into a full-fledged project and his number one priority: Figure out the best way to use all the available and upcoming medical knowledge to be as healthy as possible and to build a personal bridge into the future.
Over time this personal quest grew into a group of people, part german, part international, deeply interested in healthy longevity and extremely positive about the technological possibilities that tomorrow has in store for us.
As a private non-profit initiative, Forever Healthy's mission is to enable people to vastly extend their healthy lifespans and be part of the first generation to cure aging.
Thru various initiatives Michael both funds cutting-edge research on molecular and cellular repair to combat the root causes of aging and supports the creation of startups turning that research into therapies for human application.
Chief Business Officer, Massachusetts Biotechnology Council, Cambridge, MA
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.
John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.
Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University.
Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding.
John currently sits on the Advisory Board of MTTC (the MA Technology Transfer Center).
John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.
Co-founder & Head of Development, neotiv, Magdeburg
Julian Haupenthal was born in 1988 in Duisburg. After studying Medical engineering in Aachen, he had been working in online marketing and product management for several years. Afterwards he continued studying and finished a master degree in integrated design engineering and mechanical engineering at the University of Magdeburg, where he also had been deeply involved in the local entrepreneurship community. Since the very beginning Julian is Co-Founder of the Start-Up „neotiv “, a spin off from the German center for neurodegenerative Diseases (DZNE) and the Otto-von-Guericke University Magdeburg. neotiv develops efficient mobile solutions for the early detection of dementia and Alzheimer’s.
2007-2011 Medical Engineering – Aachen
2011-2013 Online marketing and product management lifestyle products
2013-2015 Integrated Design Engineering (M.Sc.) – Magdeburg
Since 2014 Participation in different founding projects
Since 2015 Co-Founder und Head of Development neotiv
Partner, Morse, Barnes-Brown & Pendleton, Boston
John Hession represents emerging-growth companies, principally in the medical device, life sciences, software and digital media fields, as well as angels and venture capital funds in the investment process in these areas. His practice includes both start-up and later-stage company work; equity-based compensation strategies; public offerings, representing either underwriters or companies; mergers and acquisitions, representing either buyers or sellers; corporate partnering, joint ventures and other strategic alliances involving technology transfers; license and distribution arrangements for medical devices and biotechnology, software and hardware companies; and venture capital or angel financings of technology companies, representing either investors or companies.
Mr. Hession lectures frequently on corporate partnerships, technology licensing and venture capital financings, at both national and local forums. He has authored or co-authored numerous books, articles and trade group presentations on venture capital financings, strategic alliances and technology licensing, including chapters from published books or industry conferences "Venture Capital Financings," "Website Development and Hosting Contracts," "Structuring and On Negotiating Strategic Alliances," "Internet and e-Commerce Law," and "A Technology Licensing Primer." He also has been an adjunct professor at Boston College Law School, where he taught a course for several years entitled "Venture Capital Fund Formations and Investments," and also served as an adjunct professor for several years at Boston University Law School, where he taught courses on intellectual property licensing, legal aspects of electronic commerce, and general technology licensing.
He joined the Boston-based firm, Morse, Barnes-Brown & Pendleton, PC in 2015.
Manager Technology Transfer, Center for Innovation and Business Creation, UnternehmerTUM, Munich
Since 03/2011: UnternehmerTUM GmbH – Centre for Innovation and Business Creation at Technische Universität München, Garching
Since 11/2013: Executive director pre-INCUBATION (with management responsibility)
Tasks in addition to the previous position:
- Overall responsibility and control of the pre-INCUBATION group, with the aim of identifying technology and growth-oriented start-ups at the research stage and pre-incubate them.
- In-depth methodological expertise on the subject of business development, business model generation and design thinking in the various phases of the business creation process.
03/2011 to 10/2013: Project Leader Technology and Innovation Management
- Systematic activation and awareness-raising of the target group of scientists with the aim of identifying technologies relevant for start-ups with innovation potential within the faculties of the Technische Universität München
- Design and implementation of a comprehensive process for identifying, assessing and evaluating technologies relevant to start-ups with innovation potential
- Design, implementation and running of workshops and formats for business model generation, market assessment and segmentation, as well as for the development of value proposition and customer benefit
12/2010 - 02/2011: Relocation to Munich
10/2009 - 11/2010: Human Technology Styria GmbH, Graz, Austria, Project Manager Business Development and Technology Transfer
- Leadership and management of innovation and promotion projects. Initiation, customer acquisition and processing.
- Business development and location development, process design, community building and conception/facilitation of events.
- Support of existing members and acquisition of new members of the cluster. Interface management, contact brokering and networking.
05/2006 - 09/2009: Austrian Institute of Technology GmbH - AIT, Seibersdorf, Austria
08/2007 - 09/2009: Innovation consultant and Technology Transfer Manager at Technology Transfer Center Leoben (branch of the AIT, Leoben)
- Initiation, project management and coordination of R&D projects and training projects. Customer acquisition, handling funding and project design
- Consulting: Innovation potential analyses, interface optimization and support of innovative projects
- Design, implementation and facilitation of workshops: Seminars and networking events on relevant R&D topics
05/2006 - 07/2007: Project staff member at the Office of Technology Transfer (Seibersdorf)
- Desktop Research, Market Analysis and Reporting in innovation projects
Director, Special Projects, The Engine, Boston
Kathleen is Director, Special Projects, for the Executive Vice President and Treasurer of MIT, working as a lead organizer of The Engine (www.engine.xyz), a new MIT initiative created to advance innovation. This venture fund and accelerator program will provide comprehensive support to transformative ideas from the formative stage to their most effective implementation.
In 2014, she co-founded HUBweek, a first-of-its-kind civic collaboration and weeklong festival that brings together the most creative and inventive minds making an impact in art, science and technology. HUBweek is a partnership between The Boston Globe, Harvard University, MIT and Massachusetts General Hospital and Kathleen currently serves on the executive board.
She was President of MIT Technology Review, where she led the business, redefined the iconic magazine brand, and expanded the global reach. She also served six years as President of the MIT Enterprise Forum, MITs global entrepreneurial support organization. She was an advisor for Good Growth Capital.
She started her career in accounting at Deloitte and Touche, but quickly found her true calling and left the financial world to join a startup which specialized in media research for the film industry. She studied accounting at James Madison University and she was in the Rising Scholar program at the University of Virginia.
Kathleen is a frequent speaker at technology and entrepreneurship events around the world and is a skilled moderator on a wide variety of topics. She is very active in the community, serving as a judge for many competitions including the, MacArthur Foundation, the Inclusive Innovation Competition, and the Lemelson-MIT prizes, also known as the “Nobel Prize for Innovators.”
She was awarded the Folio: 40, which recognizes the most innovative and influential people in the media industry, and named by the Women of the Harvard Club as one of Boston’s Most Influential Women of 2017.
Founder & CEO, Scopis, Berlin
Bartosz Kosmecki is the Founder and CEO of Scopis, one of the top vendors and innovators for surgical navigation systems. Bartosz Kosmecki`s success in creating innovative and disruptive products in collaboration with key opinion leaders is accompanied by his extensive experience in business development. He is driven by the challenge to solve medical problems using newest innovative technology focusing on Augmented Reality.
Prior to his entrepreneurial career, he finished his studies in Computer Engineering at Technical University Berlin, specialized in the field of Medical Engineering. During his studies, he focused both on surgical navigation and the application of augmented or mixed reality.
Scopis is a leader in medical augmented reality (AR) and Hybrid Navigation®, creating innovative solutions for the healthcare market, including technology for surgical education, and planning and navigation systems for otorhinolaryngology (ENT), craniomaxillofacial (CMF), spine, and neurosurgery. In over 50 countries worldwide, surgeons have performed more than 10,000 surgeries with the aid of Scopis’ products and have benefitted from the highly-advanced image guidance and visualization capabilities of Scopis’ technology.
State Secretary, Senate Department for Education, Youth, and Science, Berlin
Born on 7 August 1979 in Hanover
Since December 2014: Permanent Secretary for Science, Senate Department for Education, Youth and Science
2012-2014: Head of the Federation-State Coordination Office, SPD Parliamentary Group in the German Bundestag
2011-2012: Head of the Office of Senator Sandra Scheeres, Senate Department for Education, Youth and Science
2010-2011: Head of the Office of Senator Prof. Dr. Jürgen Zöllner, Senate Department for Education, Youth and Science
2008-2010: Policy Officer for Planning and Parliamentary Affairs, Senate Department for Education, Youth and Science
2007: Personal Assistant to Senator Prof. Dr. Jürgen Zöllner, Senate Department for Education, Youth and Science
2006: Policy Officer for Science, Continuing Education, Research and Culture in Rhineland-Palatinate to the Federal Government and the European Union, Representation of Rhineland-Palatinate to the Federation
2005: Degree in political science
2002-2005: Studied political science at the Otto Suhr Institute, Freie Universität Berlin
2000-2002: Studied social sciences at Georg-August-Universität, Göttingen
1999-2000: Alternative service (in lieu of military service) in Hameln
1999: University entrance examination in Hanover
2002-2005: Member of the board and vice-president of the German Student Union (DSW)
2002-2005: Member of the national executive board of the Juso (Young Socialists) university groups
2002-2005: Consultative member of the SPD executive committee
Since 1998: Member of the SPD
Co-founder & Managing Partner, Flying Health Incubator, Berlin
Christian Lautner is Co-Founder & Managing Partner at Flying Health. The Flying Health Incubator is focusing on serious digital health technologies www.flyinghealth.com i.e. digital biomarkers and digital therapies.
Previously, he co-founded one of the first German doctors rating platform imedo.de and later joined qualitaetskliniken.de as CEO to work towards comparability of hospital quality accessible for everyone via digital devices.
CEO, German Accelerator Life Sciences, Cambridge, MA
Christoph is Executive Vice President at Blueprint Medicines (BPMC) in Cambridge, MA. He has a proven record in cancer drug discovery, including contributing to 22 development candidates, 13 drugs or programs that reached first-in-human clinical trials and three approved drugs. He joined Blueprint Medicines from Sanofi, where he was Vice President and Global Head of Oncology Drug Discovery and Preclinical Development. Before joining Sanofi, Christoph was Executive Director and Senior Unit Head of Oncology Discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine where he worked with Drs. Bert Vogelstein and Ken Kinzler for more than ten years.
Christoph discovered that all cancers are genetically unstable and was involved in the identification of several oncogenic driver genes. He has authored more than one hundred scientific articles published in top-tier scientific journals, including Nature and Science. He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller “The Immortal Life of Henrietta Lacks.” Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg, Germany and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph has received numerous awards including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship. He was awarded the Novartis Oncology’s President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.
Christoph is also Venture Partner at Third Rock Ventures. In the fall of 2015, he was appointed by the German Federal Ministry for Economic Affairs & Energy to lead the build-out of the German Accelerator Life Sciences in Cambridge.
Associate, Digital Health Ventures, Berlin
Clara Leonard is an Associate at Digital Health Ventures (DHV). Prior to joining DHV, Clara worked at Sanofi in San Francisco and Paris as a scout and project leader for Digital Health solutions. She gained a sharp knowledge of the Digital Health ecosystem by sourcing opportunities for partnerships with cutting edge startups and actively contributed to large scale projects such as the joint venture between Verily (former Google Life Sciences) and Sanofi in Diabetes management.
She also acquired operational startup experience in a Business Development role at a French tech startup which successfully qualified for Y Combinator.
Clara holds a double Master degree in Management from HEC Paris and Ecole Polytechnique, with a specialization in Project Management and Innovation. She studied and worked in France, Germany, USA and Australia, where she earned experience in Strategy Consulting and Private Equity.
Director, Product Innovation, InterSystems, Cambridge, MA
Qi Li, M.D., M.B.A., is a successful healthcare innovator with extensive experience in product inception, research, and global business development. Dr. Li holds the position of director of product innovation at InterSystems in charge of the global clinical product strategy. Dr. Li has held various product leadership roles at Harris Healthcare, Partners Healthcare, and several startup companies in healthcare IT. Previously, as the key person driving the Harris Healthcare global product strategy and sales effort, Dr. Li led the product positioning and market entry efforts in UK and China. At Partners HealthCare in Boston, Dr. Li led the internal development of the Longitudinal Medical Record (LMR) adopted enterprise-wide by 7,000-plus physician users at all primary care and specialty clinics. Dr. Li consulted for Partners Medical International and taught in the China Initiative at Harvard School of Public Health. Dr. Li is on the board of MIT Hacking Medicine Institute and advises startups and innovation centers globally. Dr. Li earned his combined M.D. and M.B.A. degrees from Tufts University School of Medicine in Boston, Mass and a bachelor’s degree from University of Southern Maine. Dr. Li also attended Shanghai Jiaotong University before moving to US in 1991.
Partner, Cooley, Boston
Michael J. McGrail's practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Mike is fluent in German, and a significant portion of his practice is devoted to international transactions.
- Boston College Law School, JD, 2001, cum laude
- Northeastern University, BA, 1993, magna cum laude
- District of Columbia
- German American Business Counsel
Vice President, Innovation and New Ventures, Flex, Cambridge, MA
Babak has over 14 years of industry experience in designing and commercializing technologies. In his current role at Flex, he is responsible for setting up and managing the operations of Flex’s new Boston Innovation Center. Babak is a prolific entrepreneur, innovator, and engineer. His primary expertise is in medical device commercialization, spanning ideation through regulatory approval, marketing, and strategic sales. In his previous role at Philips Healthcare, Babak led a team of clinical scientists to establish Phillips as the market leader in cardiac care. He has won various awards, holds 43 patents, has authored/co-authored 3 books, has over 50 peer-reviewed publications and is a judge and mentor for the MIT 100K competition. Babak holds an MS in Quantum Physics from Heinrich-Heine University, a PhD in Biomedical Engineering from the University of Utrecht and an MBA from MIT Sloan School of Management.
Co-founder & Managing Partner, Flying Health Incubator, Berlin
Dr. Markus Müschenich is a board certified pediatrician and holds a Master degree in Public Health. For more than 10 years he has been a board member of non-profit and private hospital groups He is founding and board member of the German Association for Internet Medicine and Venture Partner in the investment team of Peppermint Venture Partners.
Dr. Markus Müschenich is Managing Partner of the Flying Health Incubator which focuses on digital health startups developing Digital Biomarkers & Software-as-a-Drug solutions. Dr. Markus Müschenich is regarded as a specialist for digital medicine of the future.
Deputy Chief of Mission, State of Israel in Berlin
Since 2014 Minister, Embassy of Israel Berlin
2013 – 2014 Acting Head, Asia and the Pacific Division, Ministry of Foreign Affairs
2012 – 2013 Deputy Head, Asia and the Pacific Division, Ministry of Foreign Affairs
2009 – 2012 Consul-General in Guangzhou, the first Israeli Consul-General to South-East China
2007 – 2009 Ambassador to Cameroon and Non-Resident Ambassador to Gabon, Equatorial Guinea, Central African Republic and the Republic of Congo
2005 – 2007 Director, North-East Asia Department, Ministry of Foreign Affairs
2003 – 2005 Ambassador to Vietnam and Non-Resident Ambassador to Laos
2000 – 2003 Ambassador to Nepal
1999 – 2000 South and South-East Asia Department, Ministry of Foreign Affairs
1997 – 1999 DCM, Embassy of Israel in Bangkok and Deputy Permanent Observer of Israel to ESCAP
1994 – 1997 Deputy Consul General, Shanghai, the first Israeli Diplomat to serve in Shanghai
1992 – 1994 Fellow, 'Rothchild Foundation', Special Chinese studies program of the Ministry of Foreign Affairs and the 'Rothchild Foundation', 1 semester at the Hebrew University and 3 semesters at the Beijing University
1991 – 1992 Cadet training, Ministry of Foreign Affairs
Married to Iris and father of Yotam and Atalya
BA in History and East Asia studies
Speaks Hebrew, English and Chinese
Decoration – 'Grand officer de L'ordre de la Valeur', by the President of Cameroon (Feb., 2009)
Michael J. Nowak
Managing Partner, Nowak Ventures, Boston
Michael J. Nowak
Dr. Michael J. Nowak is an experienced healthcare and high tech investor in small cap public and venture-backed private companies. He is Managing Partner of his own consulting and advisory firm and has prior experience with healthcare and life sciences focused investment funds, family offices and boutique investment banks. He was previously a Managing Director and Head of Healthcare Investments for $B multinational hedge fund Yorkville Advisors. Before that he led investments and sat on numerous Boards of Directors while a General Partner at leading $B Euro-US venture capital fund TVM Capital. He was also a corporate venture capitalist and business development executive at Xerox PARC in Palo Alto, where he was CEO of two startups, a strategic management consultant and Vice President at McKinsey & Co., and a Program Manager at the Advanced Technology Program, National Institute of Standards and Technology, US Department of Commerce.
Dr. Nowak earned an MBA from the Wharton School at the University of Pennsylvania and a PhD in Physics from the University of California, Santa Barbara. He worked as a post-doctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA research labs in Saclay and the University of Paris VI (Jussieu) in France. He received his BA in Physics from Cornell University in Ithaca, NY, where he was a College Scholar.
Director, Advanced Technology Center, The Chaim Sheba Medical Center, Tel Aviv
Director of Advanced Technology Center at the Sheba Medical Center. Prof. Orenstein obtained his MD at Tel Aviv University (1971), where he specialized in plastic surgery. He is a world expert in laser applications in medicine in general and in clinical application of photodynamic therapy (PDT) of skin cancer in particular. He was involved with the end use in the development of many medical lasers and was the initiator of the ATC concept at the Sheba Medical Center. He published more than 120 articles in the most popular magazines in Medicine. He is a Head of Bio Med Investments Committee, “100 Angels Plus” & Board Member of HipHop, Health Watch, Hospitech and Lapidot.
Head, Strategy & Operations, German Accelerator Life Sciences, Cambridge, MA
Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. In her current role as Head of Strategy & Operations at the German Accelerator Life Sciences (GALS), she works with startups and emerging companies from Germany that focus on life sciences and facilitates their successful US market entry. Prior to joining GALS in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Stiftung Charité in Berlin. Annika has served as advisor and mentor to many startups through groups such as Astia, SPARK, and MIT Hacking Medicine.
Research Associate, Cluster of Excellence Image Knowledge Gestaltung, Humboldt University, Berlin
Moritz Queisner is a researcher with an academic background in Media Studies and Science and Technology Studies. His research covers augmented reality, computer simulation and medical imaging. He is a research associate at the Cluster of Excellence Image Knowledge Gestaltung. An Interdisciplinary Laboratory of Humboldt University Berlin. His portfolio is available online at www.moritzqueisner.de.
Co-Founder, Peppermint VenturePartners
Joachim Rautter is a co-founder of Peppermint VenturePartners and Managing Partner of Peppermint Charité Biomedical Fund.
Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CryoTherapeutics GmbH and Labfolder GmbH.
Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies.
Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.
Principal, New Products, Google, Hamburg
Jens Redmer is responsible for New Products at Google. Jens joined Google in 2005 and was previously responsible for New Business Development for Google's efforts in Europe. Before that, Jens was heading up the Google Book Search Partner Programme in EMEA, partnering with up book publishers and libraries.
Jens joined Google from Endemol Germany, the world's largest independent television producer, where he was director of multimedia between 2004 and 2005.
Between 1998 and 2001, Jens was Board Member of publicly listed ricardo.de, the then-premier European online auction service which was bought out by qxl.com in 2000. He ran Premium/ Paid Services for internet service provider AOL in Germany between 2001 and 2004.
Jens began his career with German publishing group Axel Springer in Hamburg. In the period 1995-98 he played a key role in establishing Springer's first new media operations before becoming regional Managing Director for the group's nascent internet service provider, a joint venture with fellow publishing houses Bertelsmann and WAZ.
Jens holds a degree in computer science/ medicine from Kiel University, Germany.
Jens is a member of the Supervisory Board at PON Holdings, the Netherlands based mobility conglomerate and exclusive importer for Volkswagen, Porsche and Audi.
He enjoys H₂O in every aggregate state with water, winter and air sports. Likes: Water in any state of aggregation (Snow, water, and airsports). The smell of new hardware. Dislikes: Inertia. The smell of old taxis.
Managing Director, German Tech Entrepreneurship Center, Berlin
Since the age of 15, Benjamin has been working in the tech, renewable energy, and digital industry founding several companies and became an active early-stage investor in 2007. He advised DAX companies in the field of innovation and entrepreneurship. Benjamin is a lecturer and speaker at several European universities and conferences, including the Economic Forum and Zeppelin University – where he also helped to create an investment fund for university startups. Benjamin started the GTEC initiative in 2014.
Founder & CEO, Plasmatica, Israel
Graduate of Executive MBA program at Recanati business school in Israel. Founded Plasmatica in 2016 and is lately one of the gold award winners of MassChallange Israel accelerator program. Plasmatica aims to solve visibility issues in Minimal Invasive Surgery, by doing so we cut down surgery times, make the surgeons lives easier and save patients lives.
Director, GestureTek Health, London
Prior to co-founding IIP Varun has been an entrepreneur and fund manager across multiple global markets for over 17 years working across for profit and not for profit organizations such as Acumen, Unilever, CARE and Oxfam in addition to building and successfully exiting his own ventures.
Varun is on a range of global advisory boards and fund investment committees focused on emerging markets and sustainable investing. He has been widely quoted in international media over the years and is a Chevening Scholar from the London School of Economics, a TED India Fellow and an Asia Society Global Young Leader.
Igor M. Sauer
Head, Experimental Surgery, Department of Surgery, Charité, Berlin
Igor M. Sauer
Prof. Igor M. Sauer is a surgeon at the Department of Surgery, Charité – Universitätsmedizin Berlin, Germany. In addition to his clinical work, he directs research in the field of Experimental Surgery and Regenerative Medicine with a focus on cell-based therapies, extracorporeal liver support devices, and tissue engineering. He developed extracorporeal liver support systems based on detoxification techniques and primary human hepatocytes, tracking technology for transplanted hepatocytes as well as procedures for decellularization and recellularization of abdominal organs.
Head mounted displays for mixed reality seamlessly merge a real environment – e.g. the surgical site – with digital objects, e.g. important anatomical structures. His team started to develop and evaluate use-cases of this new technology in teaching, pre-surgical planning, image-assisted surgery, and tele-consulting.
Igor Sauer received his medical degree from Charité Medical School and completed his residency in general surgery at the Clinic for Visceral and Transplantation Surgery at the Hanover Medical School, Hanover, Germany.
Australian Patent and Trademark Attorney, ULLRICH & NAUMANN, Heidelberg
Dr. Daniel Schaft was awarded a PhD from the University of Giessen for his biochemical and proteomic identification and analysis of native histone deacatylase and histone methyltransferase complexes at the European Molecular Biology Laboratory (EMBL) in Heidelberg and at the Biotechnology Center of the Technical University of Dresden (BIOTEC).
At the Victor Chang Cardiac Research Centre in Sydney, Dr. Schaft studied cardiac transcription factor complexes with relevance in congenital heart disease using cardiac stem cell models both as a post-doctoral fellow of the German Research Foundation (DFG) and of the Human Frontier Science Programs (HFSP).
Having completed a Master of Intellectual Property Law at the University of Sydney, and having qualified as an Australian and New Zealand Patent Attorney, Dr. Schaft worked at one of the largest Australian intellectual property law firms for many years. Having returned to Germany, at ULLRICH & NAUMANN in Heidelberg, Dr. Schaft continues to assist large corporate life science and pharmaceutical companies, small and medium-sized enterprises, biotech start-ups as well as individual inventors/entrepreneurs in protecting their intellectual property and in successfully bringing their inventions to the market.
Partner, Syncona, London
Dominic Schmidt is a Partner of Syncona. Prior to joining Syncona, he was a member of the life science team at strategy consultancy L.E.K. Consulting, where he worked on a variety of strategy projects for Biotech, Pharma and Healthcare companies. Dominic received his Ph.D. from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics. His research has been honoured with national and international prizes and published in Cell, Nature and Science.
Johannes Schneider Littfeld
Managing Partner, BioMedTech Consult, Frankfurt
Johannes Schneider Littfeld
Johannes Schneider Littfeld, MSc Biomedical Engeneering, has been in clinical research in endocrinology at the Universities Giessen, Germany and Minneapolis, US, before he started his industry career in the consulting firm Sudler & Hennessey, Frankfurt. He than has been as Managing Director/CEO with Ferring Biotechnik, Disetronic Medical Systems, Becton Dickinson and Bauerfeind. He succesfully started new businesses in new territories and brought new technologies from R&D to market. He serves as Corporate Vice President at Otto Bock HealthCare and is Board Member of several international Healthcare companies.
Program Director, Germany, German Accelerator Life Sciences, Munich
Jared Sebhatu is the Program Director, Germany for the German Accelerator Life Sciences. He is responsible for engaging with life science startups and young companies and liaising with strategic partners. Having worked for numerous international companies, Jared is an expert in the German healthcare market and has extensive experience in the digital health and medical technology innovation process. He is currently mentoring various startups in strategy, technology, and innovation management.
CEO & Co-founder, InnoSphere, Haifa
Rami has been engaged in the high-tech industry since 1999, where he participated in the management of the investment activity of Mr. Eitan Wertheimer, one if the major private equity funds in Israel.
Throughout his career, Rami has consulted and represented various entities in the industry, ranging from banks to startups.
Rami is a registered lawyer in Israel, holding a Master’s degree in Law and founded his law firm in 2008, specializing in business, IP and corporate law.
In 2012, Rami founded a polymer manufacturing company Haifa Polymers LTD., employing 31 employees running a 24/7 production activity, and lase year he made an exit by selling the company.
Rami is the CEO and Co-founder of InnoSphere, a medical device startup developing a wearable neuro-stimulation solution for treating ADHD.
Founder, mHealth, Israel
Levi Shapiro is the Founder of mHealth Israel, a non profit supporting Israel’s digital health startup community, with more than 4,000 members. mHealth Israel hosts Israel’s largest digital health conference, September 14th, with more than 700 health tech innovators. Levi is also an Adjunct Professor at IDC Herzliya, in the Adelson School of Entrepreneurship. He writes about healthcare and technology in the Jerusalem Post and advises several prominent global medtech and biotech companies.
During a career spanning more than two decades, including seven years in Beijing and Tokyo, Mr. Shapiro launched new business units (IBM), new products and services (Toyota) and a variety of technology startups (Two Minute Television, Snack Mobile, etc). He is an investor and Board Member in several Israeli connected health startups and formerly a General Partner in the Israel-based venture capital firm, Veritas. Mr. Shapiro holds degrees from Tulane (BA), Cornell (Asian Studies) and MIT (MBA).
Senior Director, Global Partnerships, MassChallenge, London
Kara Shurmantine works at the intersection of public policy, private sector innovation, and early-stage entrepreneurial development. She is focused on strengthening startup ecosystems through effective collaboration and the generation of sustainable economic value through innovation.
As the Senior Director of Global Partnerships at MassChallenge, the most startup-friendly accelerator on the planet, she directs MassChallenge global partnerships through Bridge to MassChallenge and helps manage the organization's international expansion strategy and growth initiatives.
Kara has helped establish MassChallenge accelerators in London and Mexico City, and through the Bridge to MassChallenge partnerships has helped establish a MassChallenge presence in Australia, Colombia, France, Korea, Spain, Morocco, and beyond.
Prior to joining MassChallenge, Kara worked for a California-based venture-backed edtech startup, StudySync, and the federal government of Chile. Kara graduated Summa Cum Laude from Middlebury College in Middlebury, Vermont, with a degree in English & American Literatures and Spanish. In 2015, The Boston Globe recognized Kara as one of "Boston's 25 Most Innovative People Under 25."
Chairman & CEO, Atea Pharmaceuticals, Boston
Dr. Sommadossi is the Founder, Chairman and CEO of Atea Pharmaceuticals. Jean-Pierre has over 30 years of scientific, operational, strategic and management experience in the biotech industry. Previously Jean-Pierre was the Principal Founder of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and a Co-Founder of Pharmasset, Inc. (NASDAQ: VRUS). Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014 and Pharmasset by Gilead for $11 billion in 2012. Jean-Pierre held a number of key executive positions at Idenix, including Chairman of the Board of Directors, Executive President and Chief Scientific Officer from 1998 to 2000, and then as Chairman and Chief Executive Officer from 2000 to 2010. He is a member of the Harvard Medical School Therapeutics Advisory Council and the Harvard Medical School Discovery Council, Chairman of the Board, Panchrest, Inc., Chairman of the Board, Kezar Life Sciences, Inc., Vice-Chairman, Cornerstone Pharmaceuticals, a Member of the Board of The BioExec Institute and a Senior Advisor to PureTech Ventures, as well.
Prior to his entrepreneurial career, Jean-Pierre was on the faculty of the University of Alabama at Birmingham School of Medicine since March 1985. He served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology from June 1992 to November 2000. He has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of cancer and infectious diseases. Jean-Pierre holds a Pharm. D. and Ph. D. in Pharmacology from the University of Marseilles, France and was a post doctoral Fogarty fellow at the National Cancer Institute and the Medical College of Virginia, and is a recipient of a Faculty Award from The American Cancer Society.
Senior Lecturer in Finance, MIT Sloan School of Management, Cambridge, MA
Roger M. Stein is a Research Affiliate at the MIT Laboratory for Financial Engineering and an Adjunct Professor at the Stern School of Business. He was also previously a currently Senior Lecturer in finance at the MIT Sloan School of Management, holds the position of Affiliated Researcher at the Center for Risk Management Research, University of California, Berkeley. His current research interests are in the areas of systemic risk, credit risk, model risk and validation, biomedical funding, and the interface between data mining and financial theory. His TED Talk on new methods for funding early-stage biomedical innovation has received almost one million views.
In addition to his academic work, he has held a number of senior positions in industry. He was the Chief Analytics Officer at State Street GX, as well as Senior Managing Director of Product Strategy. Before this he was Managing Director of Research and Academic Relations globally for Moody’s Corporation and prior to this he was President of Moody’s Research Labs (MRL), a wholly owned subsidiary of Moody’s Corporation. Earlier in his career, Dr. Stein was co-head of research at Moody’s KMV.
Dr. Stein has written over sixty professional and academic articles and serves on the editorial boards of several finance journals. He has also co-authored two full-length texts on applied analytics: Active Credit Portfolio Management in Practice (Wiley, 2009), on practical credit risk management; and Seven Methods for Transforming Corporate Data into Business Intelligence (Prentice Hall, 1997), on commercial applications of data analytics, data mining (big data) and decision systems. He founded and was president of the Consortium for Systemic Risk Analytics and a member of the Advisory Council of the Museum of Mathematics; the Board of PlaNet Finance, USA, and the Academic Advisory Board of the EC’s SYstemic Risk Tomography Project (SYRTO). Dr. Stein holds a Ph.D. and Masters degree from the Stern School of Business, New York University, and a Bachelors degree in Mathematics and Japanese Studies from the State University of New York at Binghamton, with undergraduate minors in Russian and East Asian Studies. He has been practicing Aikido since 1980.
Program Director, Innovation & Entrepreneurship, Stiftung Charité, Berlin
Marvin has more than 10 years of experience in the field of innovation. He worked at the University of Potsdam’s Physical Chemistry group where he later co-founded a company to develop and sell hardware systems to measure oxygen non-invasively, a crucial parameter in regenerative medicine and tissue engineering. At the Leibniz Institute for Astrophysics Potsdam he defined and implemented professional knowledge and technology transfer structures - a novelty in the institute`s more than 300 years old history. With his educational background in innovation and science management, he successfully supported the adjacent research and innovation centre innoFSPEC to secure substantial funding for the next years.
In 2017 Marvin joined Stiftung Charité as Program Director for Innovation and Entrepreneurship.
Partner, New Venture Creation, UnternehmerTUM, Munich
Dipl.-Kfm. Markus Struppe, born on April 5, 1968 is a senior leader with more than 15 years of international experience in the field of healthcare, management consulting and cooperation with startups who consistently delivers a high level of internal and external customer value and satisfaction.
He has repeatedly undertaken challenging assignments that require innovative solutions to be built from scratch, or to introduce fresh approaches to existing structures.
He is recognized as a focused, hands-on leader delivering tangible results through innovation, change management and building diverse, motivated, high performing teams.
Vedrana Högqvist Tabor
CEO & Co-founder, BOOST by VLM Health, Berlin
Vedrana Högqvist Tabor
Vedrana is a CEO and co-founder of BOOST by VLM Health, aiming to prevent long-term health complications for people with autoimmune diseases.
Vedrana is a former Director of Scientific Research at Clue by Biowink. She has PhD in molecular biology from HU Berlin and has studied entrepreneurship at Stockholm School of Entrepreneurship. Before Clue she has spent about 15 years as a researcher trying to find out the mechanism behind emerging and metastasis of cancer, as well as other complex diseases, and was multiple awarded for her research work.
Vedrana’s passion and goal is to prevent late diagnosis of complex diseases through improving scientific tools we have, transforming our understanding of healthcare and usage of mobile and sensor technology. She believes that the right to information about how to maintain health should be one of our basic human rights.
In her free time, Vedrana is a mentor at SPARK Berlin, motivational speaker, and a standup comedian.
VP, Business Development, MindUP - The Digital Health Incubator, Haifa
Mr. Lior Teitelbaum is VP Business Development at MindUP – Israel’s first dedicated digital health incubator. Prior to joining MindUP Lior was Senior Director of Business Development at BioLineRx LTD, a biopharmaceutical development company, prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes and obesity. Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company.
Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. With distinction in molecular genetics from the Weizmann Institute of Science.
Managing Partner, MediFold, Nuremberg
Olaf is driven by a passion to bring disruptive technology concepts to the level of products and income generating businesses. He is a co-founder and founding CEO of various healthcare companies including Medimetrics, the company he built from scratch into one that is recognized world-wide as the pioneer and global leader in electronic oral drug delivery (www.medimetrics.com).
Innovation and business has driven his career since he obtained his MSc in Molecular Biology from the University of Cologne, followed by a Ph.D. degree at the Max-Planck Institute for Biochemistry, and a sales & marketing education at the European School of Management & Technology ESMT.
Starting in 1996 as project manager at Evotec, he set up and then headed the DNA-, RNA, Immuno Diagnostic Business (www.evotec.com). At the same time, he co-founded the analytical service provider Bioglobe (ww.bioglobe.net), now one of Germany’s most renowned and advanced laboratories for molecular genetic services.
In 2002 he took over responsibility for Directif Diagnostic Solutions where he successfully transformed a lab on a chip R&D project into a global technology leader of genetic point-of-care diagnostics, successfully competing with Philips. This attracted the attention of his Philips competitors, and in 2008 he joined Philips Research.
Working as a business innovator at their Eindhoven headquarters, he first created, expanded and then ‘spun out’ what is now the global brand, Medimetrics. The company has won acclaim for its IntelliCap® technology, the world’s first intelligent oral drug-delivery & patient monitoring capsule. In 2014, it won one of Europe’s most prestigious awards, the Accenture Technology Award and in 2015 the Frost & Sullivan Award. After securing its first 976 Mio.€ pharma development & licensing deal, Medimetrics is not longer a start-up.
In 2015 Olaf handed over his Medimetrics CEO duties and founded the Nürnberg based MediFold GmbH.
CFO & Member of the Executive Board, Berlin Institute of Health, Berlin
Rolf Zettl has over 25 years of management experience in the life science and research area. He was the founding managing director of the resource center of the German genome project and co-founder and CFO/CEO of biotech companies. He then moved to the Charité – University Medicine Berlin where he was head of corporate development. From 2008 he worked as managing director of the Helmholtz-Association of German research centers, the largest research organization in Germany, before he moved just recently to the Berlin Institute of Health as its CFO and member of the executive board. For his whole professional career, Rolf was involved in tech transfer, business development, and financing activities. He will built on this knowledge to establish an ecosystem for innovation at the Berlin Institute of Health. Rolf is a biologist by training and did his PhD at the Max Planck Institute for plant breeding research in Cologne, Germany.